Related Experiment Videos
Ifosfamide and ACNU in experimental allogeneic bone marrow transplantation
W Gassmann1, A Erbersdobler, L Uharek
12nd Department of Internal Medicine, University of Kiel, Federal Republic of Germany.
Journal of Cancer Research and Clinical Oncology
|January 1, 1991
Summary
Ifosfamide and ACNU show promise in preventing bone marrow graft rejection, with specific doses nearly matching cyclophosphamide's effectiveness. This research compares their engraftment-promoting potency in allogeneic bone marrow transplantation.
Area of Science:
- Immunology
- Hematology
- Pharmacology
Background:
- Allogeneic bone marrow transplantation (BMT) requires effective immunosuppression to prevent graft rejection.
- Busulfan, used to condition recipients, has weak immunosuppressive properties, necessitating additional agents.
- Cyclophosphamide is a standard agent for preventing graft rejection in BMT.
Purpose of the Study:
- To evaluate the efficacy of ifosfamide and ACNU in preventing graft rejection after allogeneic bone marrow transplantation.
- To compare the engraftment-promoting potency of ifosfamide and ACNU against cyclophosphamide.
Main Methods:
- LEW rats received busulfan followed by allogeneic F1 marrow cells.
- Graft rejection was assessed by monitoring hematocrit and granulocyte counts.
- Donor-type skin grafts were used to confirm persistent allogeneic hematopoiesis in survivors.
Main Results:
- Cyclophosphamide prevented rejection at doses of 120 mg/kg and higher.
- ACNU prevented rejection at doses of 20 mg/kg and higher.
- Ifosfamide prevented rejection at doses of 240 mg/kg and higher.
- 240 mg/kg ifosfamide or 20 mg/kg ACNU demonstrated potency comparable to 120 mg/kg cyclophosphamide.
Conclusions:
- Ifosfamide and ACNU are effective in preventing marrow graft rejection in allogeneic BMT.
- These agents offer potential alternatives to cyclophosphamide for engraftment promotion.